[177Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease

Visual Abstract We report the dosimetric evaluation of prostate-specific membrane antigen–based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. Methods: The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. Results: The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. Conclusion: This case suggests that [177Lu]Lu-PSMA–based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.

[1]  C. Stokke,et al.  EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  K. Rahbar,et al.  Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.

[3]  W. Oyen,et al.  EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  R. Baum,et al.  177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney , 2019, The Journal of Nuclear Medicine.

[5]  D. Murphy,et al.  [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[6]  K. Rahbar,et al.  177Lu-PSMA Radioligand Therapy for Prostate Cancer , 2017, The Journal of Nuclear Medicine.

[7]  E. Demirci,et al.  Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry , 2017, Molecular imaging and radionuclide therapy.

[8]  A. Sohlberg,et al.  Fast voxel-level dosimetry for 177Lu labelled peptide treatments , 2015, Physics in medicine and biology.

[9]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Carlo Chiesa,et al.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  J. Daugirdas.  Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. , 1993, Journal of the American Society of Nephrology : JASN.